Última actualización 18 de julio de 2026
Key finding
Clinically meaningful and statistically significant improvements in HbA1c were observed with CT-868 at W26 (−1.61 to −2.24% points vs. placebo; all p < 0.001).
The study evaluated CT-868, a dual GLP-1/GIP receptor agonist, and found it significantly improved glycaemic control in adults with type 2 diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated CT-868, a dual GLP-1/GIP receptor agonist, and found it significantly improved glycaemic control in adults with type 2 diabetes.
Improving glycaemic control is crucial for managing type 2 diabetes and preventing complications. The findings suggest that CT-868 could be an effective treatment option, potentially offering additional benefits like weight loss, which is often a challenge for diabetic patients.
The study's population may not be representative of all adults with type 2 diabetes. Long-term effects of CT-868 were not assessed in this trial. The sample size and duration may limit the generalizability of the findings.
Published in
Publication details and source links for this paper.
Manu VC, Michael AE, Luis A, et al. CT-868, a Dual GLP-1/GIP Receptor Agonist, Improves Glycaemic Control in Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2025;28(3):1673-1682. doi:10.1111/dom.70006
CT-868 showed a significant reduction in HbA1c by -1.92% (p < 0.001).
Fasting plasma glucose decreased by -35.1 mg/dL with CT-868 (p < 0.001).
Body weight was reduced by -2.9% with CT-868 4.0 mg (p < 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to CT-868 1.75 mg, Canagliflozin and Adverse events incidence, Body weight, Change from baseline in 7-point self-monitored blood glucose, and 2 more.
This study contributes evidence to
Primary intervention
CT-868 1.75 mg
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
10
Evidence pairs
761
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Canagliflozin → Adverse events incidence
Canagliflozin → Adverse events incidence
Canagliflozin → Change from baseline in 7-point self-monitored blood glucose
Canagliflozin → Change from baseline in 7-point self-monitored blood glucose
Canagliflozin → Fasting Plasma Glucose (FPG)
Canagliflozin → Fasting Plasma Glucose (FPG)
CT-868 1.75 mg → Adverse events incidence
CT-868 1.75 mg → Adverse events incidence
CT-868 1.75 mg → Change from baseline in 7-point self-monitored blood glucose
CT-868 1.75 mg → Change from baseline in 7-point self-monitored blood glucose
CT-868 1.75 mg → Fasting Plasma Glucose (FPG)
CT-868 1.75 mg → Fasting Plasma Glucose (FPG)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Change from baseline in 7-point self-monitored blood glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Change from baseline in 7-point self-monitored blood glucose
Measures Change from baseline in 7-point self-monitored blood glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
CT-868 1.75 mg appears to improve Body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
